Table 2. Activity of vemurafenib.

	Cohort 1 (n=26)	Cohort 2 (n=22)
Best overall response (confirmed)
Complete response	0	0
Partial response	10 (38·5%, 20·2-59·4)	6 (27·3%, 10·7-50·2)
Stable disease	15 (57·7%, 36·9-76·7)	14 (63·6%, 40·7-82·8)
Progressive disease	1 (3·8%, 0·1-19·6)	1 (4·5%, 0·1-22·8)
Unknown	0	1 (5%)

Data are number of responses (%, 95% CI). Cohort 1 includes patients who have never received a multikinase inhibitor and cohort 2 includes those previously treated with a multikinase inhibitor. The analysis population included patients with at least two post-baseline tumour scans or progressive disease, worsening disease, death, or an adverse event within the first two cycles.